Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Inhibition profiles of phosphatidylinositol 3-kinase inhibitors against PI3K superfamily and human cancer cell line panel JFCR39.

Kong D, Dan S, Yamazaki K, Yamori T.

Eur J Cancer. 2010 Apr;46(6):1111-21. doi: 10.1016/j.ejca.2010.01.005.

PMID:
20129775
2.
3.

In vitro multifaceted activities of a specific group of novel phosphatidylinositol 3-kinase inhibitors on hotspot mutant PIK3CA.

Kong D, Yamori T, Yamazaki K, Dan S.

Invest New Drugs. 2014 Dec;32(6):1134-43. doi: 10.1007/s10637-014-0152-z.

PMID:
25152245
4.

ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor identified using the JFCR39 drug discovery system.

Kong DX, Yamori T.

Acta Pharmacol Sin. 2010 Sep;31(9):1189-97. doi: 10.1038/aps.2010.150. Review.

5.

Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor.

Yaguchi S, Fukui Y, Koshimizu I, Yoshimi H, Matsuno T, Gouda H, Hirono S, Yamazaki K, Yamori T.

J Natl Cancer Inst. 2006 Apr 19;98(8):545-56.

6.

Multipoint targeting of the PI3K/mTOR pathway in mesothelioma.

Zhou S, Liu L, Li H, Eilers G, Kuang Y, Shi S, Yan Z, Li X, Corson JM, Meng F, Zhou H, Sheng Q, Fletcher JA, Ou WB.

Br J Cancer. 2014 May 13;110(10):2479-88. doi: 10.1038/bjc.2014.220.

7.

The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition.

Haagensen EJ, Kyle S, Beale GS, Maxwell RJ, Newell DR.

Br J Cancer. 2012 Apr 10;106(8):1386-94. doi: 10.1038/bjc.2012.70.

8.

Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia.

Kampa-Schittenhelm KM, Heinrich MC, Akmut F, Rasp KH, Illing B, Döhner H, Döhner K, Schittenhelm MM.

Mol Cancer. 2013 May 24;12:46. doi: 10.1186/1476-4598-12-46.

10.

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.

Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chène P, De Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W, García-Echeverría C.

Mol Cancer Ther. 2008 Jul;7(7):1851-63. doi: 10.1158/1535-7163.MCT-08-0017.

11.

NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas.

Liu TJ, Koul D, LaFortune T, Tiao N, Shen RJ, Maira SM, Garcia-Echevrria C, Yung WK.

Mol Cancer Ther. 2009 Aug;8(8):2204-10. doi: 10.1158/1535-7163.MCT-09-0160.

12.

Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia.

Chapuis N, Tamburini J, Green AS, Vignon C, Bardet V, Neyret A, Pannetier M, Willems L, Park S, Macone A, Maira SM, Ifrah N, Dreyfus F, Herault O, Lacombe C, Mayeux P, Bouscary D.

Clin Cancer Res. 2010 Nov 15;16(22):5424-35. doi: 10.1158/1078-0432.CCR-10-1102.

13.

Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against osteosarcoma.

Zhu YR, Min H, Fang JF, Zhou F, Deng XW, Zhang YQ.

Cancer Biol Ther. 2015;16(4):602-9. doi: 10.1080/15384047.2015.1017155.

14.
15.

Targeting melanoma with dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors.

Marone R, Erhart D, Mertz AC, Bohnacker T, Schnell C, Cmiljanovic V, Stauffer F, Garcia-Echeverria C, Giese B, Maira SM, Wymann MP.

Mol Cancer Res. 2009 Apr;7(4):601-13. doi: 10.1158/1541-7786.MCR-08-0366.

16.

Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.

McMillin DW, Ooi M, Delmore J, Negri J, Hayden P, Mitsiades N, Jakubikova J, Maira SM, Garcia-Echeverria C, Schlossman R, Munshi NC, Richardson PG, Anderson KC, Mitsiades CS.

Cancer Res. 2009 Jul 15;69(14):5835-42. doi: 10.1158/0008-5472.CAN-08-4285.

17.

Simultaneous perturbation of the MAPK and the PI3K/mTOR pathways does not lead to increased radiosensitization.

Kuger S, Flentje M, Djuzenova CS.

Radiat Oncol. 2015 Oct 24;10:214. doi: 10.1186/s13014-015-0514-5.

18.

Inhibition of PI3K by ZSTK474 suppressed tumor growth not via apoptosis but G0/G1 arrest.

Dan S, Yoshimi H, Okamura M, Mukai Y, Yamori T.

Biochem Biophys Res Commun. 2009 Jan 30;379(1):104-9. doi: 10.1016/j.bbrc.2008.12.015.

PMID:
19094964
19.

Comparison of the effects of the PI3K/mTOR inhibitors NVP-BEZ235 and GSK2126458 on tamoxifen-resistant breast cancer cells.

Leung E, Kim JE, Rewcastle GW, Finlay GJ, Baguley BC.

Cancer Biol Ther. 2011 Jun 1;11(11):938-46.

20.

Inhibition of autophagy enhances apoptosis induced by the PI3K/AKT/mTor inhibitor NVP-BEZ235 in renal cell carcinoma cells.

Li H, Jin X, Zhang Z, Xing Y, Kong X.

Cell Biochem Funct. 2013 Jul;31(5):427-33. doi: 10.1002/cbf.2917.

PMID:
23086777
Items per page

Supplemental Content

Support Center